Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups A, C, Y, and W-135) polysaccharide conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent meningococcal polysaccharide-protein conjugate vaccine is a biologic preparation designed to induce active immunity against *Neisseria meningitidis* serogroups A, C, W-135, and Y. Unlike plain polysaccharide vaccines, these formulations conjugate the bacterial capsular polysaccharides to a carrier protein, such as diphtheria toxoid, CRM197, or tetanus toxoid. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which enhances immunogenicity in infants, induces higher antibody titers, and promotes immunological memory. It is primarily indicated for the prophylaxis of invasive meningococcal disease, including meningitis and septicemia, in individuals ranging from infants to older adults, depending on the specific product formulation.
- Brand names
- MenactraMenveoNimenrixMenQuadfi
- Other names
- quadrivalent meningococcal polysaccharide-protein conjugate vaccinequadrivalent meningococcal conjugate vaccinemeningococcal A, C, Y, and W-135 conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)DT/CRM197 (Diphtheria toxin-derived carrier protein)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal (groups A, C, Y, and W-135) polysaccharide conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups A, C, Y, and W-135) polysaccharide conjugate vaccine.